Share Price and Basic Stock Data
Last Updated: January 23, 2026, 5:24 pm
| PEG Ratio | -1.43 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Sanofi India Ltd operates within the pharmaceuticals sector and reported a market capitalization of ₹9,294 Cr. As of the latest figures, the company’s stock price stood at ₹4,042. The revenue trends indicate fluctuations in sales, with a notable peak in March 2023 at ₹736 Cr, followed by a decline to ₹491 Cr in September 2023. The trailing twelve months (TTM) revenue is reported at ₹1,932 Cr, a decrease from ₹2,770 Cr in December 2022. This decline in sales can be attributed to several factors including market conditions and competitive pressures in the pharmaceutical industry. Over the years, the sales figures have shown variability, with the highest annual revenue recorded at ₹3,071 Cr in December 2019, followed by a dip in subsequent years, particularly during the pandemic-affected period. The company’s ability to recover from these dips will depend on its strategic initiatives and market dynamics.
Profitability and Efficiency Metrics
Sanofi India Ltd has demonstrated strong profitability metrics, with a reported net profit of ₹356 Cr and a remarkable return on equity (ROE) of 47.2%. The operating profit margin (OPM) stood at 28%, indicating solid operational efficiency compared to typical sector averages which range between 20-25%. The company recorded an interest coverage ratio (ICR) of 338.20x, showcasing its ability to meet interest obligations comfortably, a positive sign for investors. However, quarterly data reveals a declining trend in net profits, with September 2023’s profit at ₹152 Cr, down from ₹190 Cr in March 2023. The efficiency ratios, including a cash conversion cycle (CCC) of 77 days, suggest effective management of working capital, although this is higher than previous years, indicating potential liquidity challenges. Overall, the company’s profitability remains robust but is currently experiencing volatility in its quarterly performance.
Balance Sheet Strength and Financial Ratios
Sanofi India Ltd’s balance sheet reflects significant strength, with total reserves reported at ₹759 Cr and minimal borrowings of ₹21 Cr, indicating a low leverage position. The company’s debt-to-equity ratio is effectively negligible, further reinforcing its financial stability. The price-to-book value (P/BV) ratio stands at 16.36x, which is relatively high compared to industry norms, suggesting that the stock may be overvalued based on book value alone. Furthermore, total assets are reported at ₹1,239 Cr, with a current ratio of 1.57x, indicating that the company has sufficient short-term assets to cover its liabilities. However, the decline in reserves from ₹2,203 Cr in December 2021 to ₹759 Cr currently raises concerns about retained earnings and future growth prospects. The return on capital employed (ROCE) of 49.2% remains a strong indicator of efficient capital use, positioning the company favorably among its peers.
Shareholding Pattern and Investor Confidence
Sanofi India Ltd exhibits a stable shareholding pattern, with promoters holding 60.40% of the equity. This substantial promoter stake reflects strong insider confidence in the company’s performance and future prospects. Foreign institutional investors (FIIs) have reduced their holdings slightly to 5.57%, while domestic institutional investors (DIIs) hold 22.28%, indicating a relatively balanced institutional interest. The public shareholding stands at 11.75%, showing a slight increase in public participation from prior periods. The total number of shareholders has fluctuated, currently reported at 71,395, suggesting a dynamic investor interest. The consistency of promoter holdings over multiple quarters signifies stability, but the decline in FII participation could be seen as a cautionary signal for potential investors. Overall, the shareholding structure suggests a solid foundation of support from promoters and institutional investors, fostering confidence in the company’s governance.
Outlook, Risks, and Final Insight
Looking ahead, Sanofi India Ltd faces both opportunities and challenges. The company’s strong profitability, indicated by high ROE and ROCE, positions it well for future growth if it can stabilize its revenue streams and manage operational efficiencies effectively. However, risks include declining sales figures and a noticeable drop in reserves, which could hinder its capacity to invest in growth initiatives. Additionally, with increasing competition in the pharmaceuticals sector, maintaining market share will be critical. The company must also navigate potential regulatory changes that could impact its operations. In scenarios where Sanofi India manages to innovate and expand its product offerings while controlling costs, it could see a turnaround in sales and profitability. Conversely, failure to address the current inefficiencies and market pressures could lead to further declines in financial performance, necessitating strategic re-evaluations to safeguard shareholder interests.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 126 Cr. | 99.9 | 198/84.3 | 27.8 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,406 Cr. | 314 | 479/192 | 70.5 | 24.3 | 0.21 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 33.0 Cr. | 44.5 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 61.0 Cr. | 41.7 | 43.4/17.0 | 145 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,521.36 Cr | 1,088.43 | 47.54 | 202.32 | 0.38% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 692 | 672 | 736 | 515 | 491 | 469 | 511 | 464 | 524 | 515 | 536 | 406 | 475 |
| Expenses | 510 | 505 | 507 | 393 | 377 | 370 | 374 | 348 | 404 | 397 | 364 | 311 | 341 |
| Operating Profit | 182 | 167 | 230 | 122 | 114 | 100 | 137 | 116 | 120 | 118 | 172 | 95 | 134 |
| OPM % | 26% | 25% | 31% | 24% | 23% | 21% | 27% | 25% | 23% | 23% | 32% | 23% | 28% |
| Other Income | 11 | 34 | 44 | 57 | 82 | 77 | 41 | 21 | 2 | 14 | 3 | 9 | -22 |
| Interest | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 9 | 9 | 10 | 10 | 9 | 9 |
| Profit before tax | 182 | 190 | 264 | 169 | 186 | 167 | 169 | 127 | 113 | 122 | 165 | 94 | 102 |
| Tax % | 28% | 31% | 28% | 27% | 18% | 18% | 19% | 19% | 27% | 25% | 28% | 26% | 26% |
| Net Profit | 131 | 131 | 190 | 123 | 152 | 138 | 137 | 103 | 82 | 91 | 120 | 70 | 76 |
| EPS in Rs | 56.91 | 56.91 | 82.78 | 53.43 | 66.17 | 59.87 | 59.39 | 44.96 | 35.74 | 39.70 | 51.96 | 30.22 | 33.04 |
Last Updated: December 29, 2025, 6:33 am
Below is a detailed analysis of the quarterly data for Sanofi India Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 475.00 Cr.. The value appears strong and on an upward trend. It has increased from 406.00 Cr. (Jun 2025) to 475.00 Cr., marking an increase of 69.00 Cr..
- For Expenses, as of Sep 2025, the value is 341.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 311.00 Cr. (Jun 2025) to 341.00 Cr., marking an increase of 30.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 134.00 Cr.. The value appears strong and on an upward trend. It has increased from 95.00 Cr. (Jun 2025) to 134.00 Cr., marking an increase of 39.00 Cr..
- For OPM %, as of Sep 2025, the value is 28.00%. The value appears strong and on an upward trend. It has increased from 23.00% (Jun 2025) to 28.00%, marking an increase of 5.00%.
- For Other Income, as of Sep 2025, the value is -22.00 Cr.. The value appears to be declining and may need further review. It has decreased from 9.00 Cr. (Jun 2025) to -22.00 Cr., marking a decrease of 31.00 Cr..
- For Interest, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00 Cr..
- For Depreciation, as of Sep 2025, the value is 9.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 9.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 102.00 Cr.. The value appears strong and on an upward trend. It has increased from 94.00 Cr. (Jun 2025) to 102.00 Cr., marking an increase of 8.00 Cr..
- For Tax %, as of Sep 2025, the value is 26.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 26.00%.
- For Net Profit, as of Sep 2025, the value is 76.00 Cr.. The value appears strong and on an upward trend. It has increased from 70.00 Cr. (Jun 2025) to 76.00 Cr., marking an increase of 6.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 33.04. The value appears strong and on an upward trend. It has increased from 30.22 (Jun 2025) to 33.04, marking an increase of 2.82.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:41 am
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,809 | 1,977 | 2,193 | 2,367 | 2,460 | 2,771 | 3,071 | 2,902 | 2,957 | 2,770 | 1,996 | 2,013 | 1,932 |
| Expenses | 1,411 | 1,639 | 1,817 | 1,832 | 1,921 | 2,146 | 2,403 | 2,186 | 2,194 | 2,066 | 1,508 | 1,522 | 1,413 |
| Operating Profit | 398 | 339 | 376 | 535 | 538 | 625 | 667 | 716 | 762 | 704 | 488 | 491 | 519 |
| OPM % | 22% | 17% | 17% | 23% | 22% | 23% | 22% | 25% | 26% | 25% | 24% | 24% | 27% |
| Other Income | 83 | 131 | 218 | 66 | 79 | 88 | 33 | 45 | 564 | 204 | 318 | 79 | 4 |
| Interest | 0 | 0 | 0 | 2 | 1 | 1 | 0 | 2 | 2 | 2 | 2 | 2 | 2 |
| Depreciation | 92 | 97 | 113 | 119 | 102 | 103 | 100 | 82 | 67 | 42 | 36 | 37 | 37 |
| Profit before tax | 388 | 373 | 481 | 480 | 515 | 610 | 600 | 677 | 1,258 | 864 | 767 | 531 | 484 |
| Tax % | 32% | 29% | 33% | 37% | 37% | 38% | 31% | 29% | 25% | 28% | 21% | 22% | |
| Net Profit | 265 | 264 | 322 | 304 | 326 | 381 | 414 | 478 | 944 | 621 | 603 | 414 | 356 |
| EPS in Rs | 115.30 | 114.61 | 139.78 | 132.26 | 141.74 | 165.48 | 180.09 | 207.65 | 410.61 | 269.83 | 262.26 | 179.78 | 154.92 |
| Dividend Payout % | 39% | 39% | 46% | 51% | 50% | 51% | 194% | 176% | 119% | 211% | 64% | 65% |
YoY Net Profit Growth
| Year |
|---|
| YoY Net Profit Growth (%) |
| Change in YoY Net Profit Growth (%) |
No data available for trend analysis.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | -8% |
| 3 Years: | -12% |
| TTM: | 2% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 0% |
| 3 Years: | -9% |
| TTM: | 1% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 0% |
| 3 Years: | 11% |
| 1 Year: | -31% |
| Return on Equity | |
|---|---|
| 10 Years: | 24% |
| 5 Years: | 32% |
| 3 Years: | 41% |
| Last Year: | 47% |
Last Updated: September 5, 2025, 1:25 pm
Balance Sheet
Last Updated: August 11, 2025, 2:43 pm
| Month | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 |
| Reserves | 1,324 | 1,463 | 1,604 | 1,860 | 2,003 | 2,196 | 2,419 | 2,096 | 2,203 | 1,253 | 992 | 838 | 759 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 23 | 25 | 24 | 19 | 19 | 21 |
| Other Liabilities | 532 | 742 | 778 | 658 | 751 | 765 | 802 | 777 | 811 | 772 | 681 | 732 | 436 |
| Total Liabilities | 1,878 | 2,228 | 2,405 | 2,541 | 2,778 | 2,984 | 3,244 | 2,918 | 3,061 | 2,072 | 1,715 | 1,612 | 1,239 |
| Fixed Assets | 699 | 648 | 877 | 817 | 769 | 733 | 499 | 464 | 334 | 306 | 315 | 312 | 309 |
| CWIP | 136 | 210 | 22 | 34 | 30 | 21 | 17 | 10 | 13 | 24 | 16 | 18 | 16 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| Other Assets | 1,043 | 1,369 | 1,505 | 1,690 | 1,978 | 2,230 | 2,728 | 2,444 | 2,714 | 1,743 | 1,382 | 1,281 | 914 |
| Total Assets | 1,878 | 2,228 | 2,405 | 2,541 | 2,778 | 2,984 | 3,244 | 2,918 | 3,061 | 2,072 | 1,715 | 1,612 | 1,239 |
Below is a detailed analysis of the balance sheet data for Sanofi India Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Equity Capital, as of Jun 2025, the value is 23.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 23.00 Cr..
- For Reserves, as of Jun 2025, the value is 759.00 Cr.. The value appears to be declining and may need further review. It has decreased from 838.00 Cr. (Dec 2024) to 759.00 Cr., marking a decrease of 79.00 Cr..
- For Borrowings, as of Jun 2025, the value is 21.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 19.00 Cr. (Dec 2024) to 21.00 Cr., marking an increase of 2.00 Cr..
- For Other Liabilities, as of Jun 2025, the value is 436.00 Cr.. The value appears to be improving (decreasing). It has decreased from 732.00 Cr. (Dec 2024) to 436.00 Cr., marking a decrease of 296.00 Cr..
- For Total Liabilities, as of Jun 2025, the value is 1,239.00 Cr.. The value appears to be improving (decreasing). It has decreased from 1,612.00 Cr. (Dec 2024) to 1,239.00 Cr., marking a decrease of 373.00 Cr..
- For Fixed Assets, as of Jun 2025, the value is 309.00 Cr.. The value appears to be declining and may need further review. It has decreased from 312.00 Cr. (Dec 2024) to 309.00 Cr., marking a decrease of 3.00 Cr..
- For CWIP, as of Jun 2025, the value is 16.00 Cr.. The value appears to be declining and may need further review. It has decreased from 18.00 Cr. (Dec 2024) to 16.00 Cr., marking a decrease of 2.00 Cr..
- For Investments, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 0.00 Cr..
- For Other Assets, as of Jun 2025, the value is 914.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,281.00 Cr. (Dec 2024) to 914.00 Cr., marking a decrease of 367.00 Cr..
- For Total Assets, as of Jun 2025, the value is 1,239.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,612.00 Cr. (Dec 2024) to 1,239.00 Cr., marking a decrease of 373.00 Cr..
Notably, the Reserves (759.00 Cr.) exceed the Borrowings (21.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 398.00 | 339.00 | 376.00 | 535.00 | 538.00 | 625.00 | 667.00 | 693.00 | 737.00 | 680.00 | 469.00 | 472.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 24 | 21 | 24 | 22 | 29 | 21 | 27 | 19 | 18 | 17 | 24 | 42 |
| Inventory Days | 151 | 179 | 173 | 169 | 151 | 154 | 127 | 107 | 110 | 125 | 254 | 186 |
| Days Payable | 83 | 122 | 81 | 79 | 119 | 110 | 100 | 93 | 105 | 109 | 112 | 151 |
| Cash Conversion Cycle | 92 | 78 | 115 | 112 | 61 | 65 | 54 | 33 | 22 | 33 | 167 | 77 |
| Working Capital Days | 43 | 26 | 9 | 79 | 17 | 18 | 35 | -8 | -20 | -19 | 35 | 20 |
| ROCE % | 29% | 22% | 26% | 27% | 26% | 29% | 28% | 32% | 35% | 41% | 44% | 49% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| SBI Contra Fund | 251,576 | 0.22 | 110.38 | 161,000 | 2025-12-07 15:45:16 | 56.26% |
| Aditya Birla Sun Life Large Cap Fund | 250,365 | 0.35 | 109.85 | N/A | N/A | N/A |
| Nippon India Pharma Fund | 230,272 | 1.19 | 101.04 | 236,008 | 2025-12-08 04:19:42 | -2.43% |
| Nippon India Growth Mid Cap Fund | 226,766 | 0.24 | 99.5 | N/A | N/A | N/A |
| Nippon India Small Cap Fund | 213,992 | 0.14 | 93.89 | 196,342 | 2025-12-08 07:42:13 | 8.99% |
| SBI Midcap Fund | 195,082 | 0.37 | 85.6 | 250,165 | 2025-12-14 06:18:21 | -22.02% |
| Nippon India Multi Cap Fund | 152,371 | 0.13 | 66.86 | 152,371 | 2025-04-22 17:25:21 | 0% |
| SBI ELSS Tax Saver Fund | 147,988 | 0.2 | 64.93 | N/A | N/A | N/A |
| Aditya Birla Sun Life Balanced Advantage Fund | 81,404 | 0.41 | 35.72 | N/A | N/A | N/A |
| Aditya Birla Sun Life Consumption Fund | 75,252 | 0.5 | 33.02 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Dec 24 | Dec 23 |
|---|---|---|
| FaceValue | 10.00 | 10.00 |
| Basic EPS (Rs.) | 179.46 | 261.78 |
| Diluted EPS (Rs.) | 179.46 | 261.78 |
| Cash EPS (Rs.) | 195.65 | 279.35 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 374.17 | 441.39 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 374.17 | 441.39 |
| Revenue From Operations / Share (Rs.) | 875.30 | 1239.61 |
| PBDIT / Share (Rs.) | 220.57 | 377.83 |
| PBIT / Share (Rs.) | 204.61 | 360.61 |
| PBT / Share (Rs.) | 187.57 | 367.61 |
| Net Profit / Share (Rs.) | 179.69 | 262.13 |
| NP After MI And SOA / Share (Rs.) | 179.69 | 262.13 |
| PBDIT Margin (%) | 25.19 | 30.47 |
| PBIT Margin (%) | 23.37 | 29.09 |
| PBT Margin (%) | 21.42 | 29.65 |
| Net Profit Margin (%) | 20.52 | 21.14 |
| NP After MI And SOA Margin (%) | 20.52 | 21.14 |
| Return on Networth / Equity (%) | 48.02 | 59.38 |
| Return on Capital Employeed (%) | 52.72 | 77.98 |
| Return On Assets (%) | 25.64 | 35.15 |
| Asset Turnover Ratio (%) | 1.21 | 0.00 |
| Current Ratio (X) | 1.57 | 1.92 |
| Quick Ratio (X) | 0.87 | 0.89 |
| Inventory Turnover Ratio (X) | 0.60 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 139.85 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 131.23 |
| Earning Retention Ratio (%) | 0.00 | -39.85 |
| Cash Earning Retention Ratio (%) | 0.00 | -31.23 |
| Interest Coverage Ratio (X) | 338.20 | 511.18 |
| Interest Coverage Ratio (Post Tax) (X) | 235.27 | 345.18 |
| Enterprise Value (Cr.) | 13783.39 | 18147.83 |
| EV / Net Operating Revenue (X) | 6.85 | 6.37 |
| EV / EBITDA (X) | 27.17 | 20.88 |
| MarketCap / Net Operating Revenue (X) | 6.99 | 6.51 |
| Retention Ratios (%) | 0.00 | -39.85 |
| Price / BV (X) | 16.36 | 18.28 |
| Price / Net Operating Revenue (X) | 6.99 | 6.51 |
| EarningsYield | 0.02 | 0.03 |
After reviewing the key financial ratios for Sanofi India Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Dec 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Dec 23) which recorded 10.00.
- For Basic EPS (Rs.), as of Dec 24, the value is 179.46. This value is within the healthy range. It has decreased from 261.78 (Dec 23) to 179.46, marking a decrease of 82.32.
- For Diluted EPS (Rs.), as of Dec 24, the value is 179.46. This value is within the healthy range. It has decreased from 261.78 (Dec 23) to 179.46, marking a decrease of 82.32.
- For Cash EPS (Rs.), as of Dec 24, the value is 195.65. This value is within the healthy range. It has decreased from 279.35 (Dec 23) to 195.65, marking a decrease of 83.70.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Dec 24, the value is 374.17. It has decreased from 441.39 (Dec 23) to 374.17, marking a decrease of 67.22.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Dec 24, the value is 374.17. It has decreased from 441.39 (Dec 23) to 374.17, marking a decrease of 67.22.
- For Revenue From Operations / Share (Rs.), as of Dec 24, the value is 875.30. It has decreased from 1,239.61 (Dec 23) to 875.30, marking a decrease of 364.31.
- For PBDIT / Share (Rs.), as of Dec 24, the value is 220.57. This value is within the healthy range. It has decreased from 377.83 (Dec 23) to 220.57, marking a decrease of 157.26.
- For PBIT / Share (Rs.), as of Dec 24, the value is 204.61. This value is within the healthy range. It has decreased from 360.61 (Dec 23) to 204.61, marking a decrease of 156.00.
- For PBT / Share (Rs.), as of Dec 24, the value is 187.57. This value is within the healthy range. It has decreased from 367.61 (Dec 23) to 187.57, marking a decrease of 180.04.
- For Net Profit / Share (Rs.), as of Dec 24, the value is 179.69. This value is within the healthy range. It has decreased from 262.13 (Dec 23) to 179.69, marking a decrease of 82.44.
- For NP After MI And SOA / Share (Rs.), as of Dec 24, the value is 179.69. This value is within the healthy range. It has decreased from 262.13 (Dec 23) to 179.69, marking a decrease of 82.44.
- For PBDIT Margin (%), as of Dec 24, the value is 25.19. This value is within the healthy range. It has decreased from 30.47 (Dec 23) to 25.19, marking a decrease of 5.28.
- For PBIT Margin (%), as of Dec 24, the value is 23.37. This value exceeds the healthy maximum of 20. It has decreased from 29.09 (Dec 23) to 23.37, marking a decrease of 5.72.
- For PBT Margin (%), as of Dec 24, the value is 21.42. This value is within the healthy range. It has decreased from 29.65 (Dec 23) to 21.42, marking a decrease of 8.23.
- For Net Profit Margin (%), as of Dec 24, the value is 20.52. This value exceeds the healthy maximum of 10. It has decreased from 21.14 (Dec 23) to 20.52, marking a decrease of 0.62.
- For NP After MI And SOA Margin (%), as of Dec 24, the value is 20.52. This value exceeds the healthy maximum of 20. It has decreased from 21.14 (Dec 23) to 20.52, marking a decrease of 0.62.
- For Return on Networth / Equity (%), as of Dec 24, the value is 48.02. This value is within the healthy range. It has decreased from 59.38 (Dec 23) to 48.02, marking a decrease of 11.36.
- For Return on Capital Employeed (%), as of Dec 24, the value is 52.72. This value is within the healthy range. It has decreased from 77.98 (Dec 23) to 52.72, marking a decrease of 25.26.
- For Return On Assets (%), as of Dec 24, the value is 25.64. This value is within the healthy range. It has decreased from 35.15 (Dec 23) to 25.64, marking a decrease of 9.51.
- For Asset Turnover Ratio (%), as of Dec 24, the value is 1.21. It has increased from 0.00 (Dec 23) to 1.21, marking an increase of 1.21.
- For Current Ratio (X), as of Dec 24, the value is 1.57. This value is within the healthy range. It has decreased from 1.92 (Dec 23) to 1.57, marking a decrease of 0.35.
- For Quick Ratio (X), as of Dec 24, the value is 0.87. This value is below the healthy minimum of 1. It has decreased from 0.89 (Dec 23) to 0.87, marking a decrease of 0.02.
- For Inventory Turnover Ratio (X), as of Dec 24, the value is 0.60. This value is below the healthy minimum of 4. It has increased from 0.00 (Dec 23) to 0.60, marking an increase of 0.60.
- For Dividend Payout Ratio (NP) (%), as of Dec 24, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 139.85 (Dec 23) to 0.00, marking a decrease of 139.85.
- For Dividend Payout Ratio (CP) (%), as of Dec 24, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 131.23 (Dec 23) to 0.00, marking a decrease of 131.23.
- For Earning Retention Ratio (%), as of Dec 24, the value is 0.00. This value is below the healthy minimum of 40. It has increased from -39.85 (Dec 23) to 0.00, marking an increase of 39.85.
- For Cash Earning Retention Ratio (%), as of Dec 24, the value is 0.00. This value is below the healthy minimum of 40. It has increased from -31.23 (Dec 23) to 0.00, marking an increase of 31.23.
- For Interest Coverage Ratio (X), as of Dec 24, the value is 338.20. This value is within the healthy range. It has decreased from 511.18 (Dec 23) to 338.20, marking a decrease of 172.98.
- For Interest Coverage Ratio (Post Tax) (X), as of Dec 24, the value is 235.27. This value is within the healthy range. It has decreased from 345.18 (Dec 23) to 235.27, marking a decrease of 109.91.
- For Enterprise Value (Cr.), as of Dec 24, the value is 13,783.39. It has decreased from 18,147.83 (Dec 23) to 13,783.39, marking a decrease of 4,364.44.
- For EV / Net Operating Revenue (X), as of Dec 24, the value is 6.85. This value exceeds the healthy maximum of 3. It has increased from 6.37 (Dec 23) to 6.85, marking an increase of 0.48.
- For EV / EBITDA (X), as of Dec 24, the value is 27.17. This value exceeds the healthy maximum of 15. It has increased from 20.88 (Dec 23) to 27.17, marking an increase of 6.29.
- For MarketCap / Net Operating Revenue (X), as of Dec 24, the value is 6.99. This value exceeds the healthy maximum of 3. It has increased from 6.51 (Dec 23) to 6.99, marking an increase of 0.48.
- For Retention Ratios (%), as of Dec 24, the value is 0.00. This value is below the healthy minimum of 30. It has increased from -39.85 (Dec 23) to 0.00, marking an increase of 39.85.
- For Price / BV (X), as of Dec 24, the value is 16.36. This value exceeds the healthy maximum of 3. It has decreased from 18.28 (Dec 23) to 16.36, marking a decrease of 1.92.
- For Price / Net Operating Revenue (X), as of Dec 24, the value is 6.99. This value exceeds the healthy maximum of 3. It has increased from 6.51 (Dec 23) to 6.99, marking an increase of 0.48.
- For EarningsYield, as of Dec 24, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.03 (Dec 23) to 0.02, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Sanofi India Ltd:
- Net Profit Margin: 20.52%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 52.72% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 48.02% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 235.27
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.87
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 25.3 (Industry average Stock P/E: 47.54)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 20.52%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Sanofi House, Mumbai Maharashtra 400072 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Aditya Narayan | Chairman & Ind.Director |
| Mr. Rodolfo Hrosz | Managing Director |
| Mr. Rachid Ayari | WholeTime Director & CFO |
| Ms. Renee Amonkar | Whole Time Director |
| Mr. Vaibhav Karandikar | Non Executive Director |
| Mrs. Usha Thorat | Independent Director |
| Mr. Rahul Bhatnagar | Independent Director |
FAQ
What is the intrinsic value of Sanofi India Ltd?
Sanofi India Ltd's intrinsic value (as of 23 January 2026) is ₹2749.78 which is 32.27% lower the current market price of ₹4,060.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹9,349 Cr. market cap, FY2025-2026 high/low of ₹6,718/3,976, reserves of ₹759 Cr, and liabilities of ₹1,239 Cr.
What is the Market Cap of Sanofi India Ltd?
The Market Cap of Sanofi India Ltd is 9,349 Cr..
What is the current Stock Price of Sanofi India Ltd as on 23 January 2026?
The current stock price of Sanofi India Ltd as on 23 January 2026 is ₹4,060.
What is the High / Low of Sanofi India Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Sanofi India Ltd stocks is ₹6,718/3,976.
What is the Stock P/E of Sanofi India Ltd?
The Stock P/E of Sanofi India Ltd is 25.3.
What is the Book Value of Sanofi India Ltd?
The Book Value of Sanofi India Ltd is 340.
What is the Dividend Yield of Sanofi India Ltd?
The Dividend Yield of Sanofi India Ltd is 2.88 %.
What is the ROCE of Sanofi India Ltd?
The ROCE of Sanofi India Ltd is 49.2 %.
What is the ROE of Sanofi India Ltd?
The ROE of Sanofi India Ltd is 47.2 %.
What is the Face Value of Sanofi India Ltd?
The Face Value of Sanofi India Ltd is 10.0.